BACKGROUND: Treatment of older cancer patients at the end of life has become increasingly aggressive, despite the absence of evidence for better outcomes. We compared aggressiveness of end-of-life care of older metastatic cancer patients treated in the Veterans Health Administration (VHA) and those under fee-for-service Medicare arrangements. METHODS: Using propensity score methods, we matched 2913 male veterans who were diagnosed with stage IV lung or colorectal cancer in 2001-2002 and died before 2006 with 2913 similar men enrolled in fee-for-service Medicare living in Surveillance, Epidemiology, and End Result (SEER) areas. We assessed chemotherapy within 14 days of death, intensive care unit (ICU) admissions within 30 days of death, and >1 emergency room visit within 30 days of death. RESULTS: Among matched cohorts, men treated in the VHA were less likely than men in the private sector to receive chemotherapy within 14 days of death (4.6% vs 7.5%, P<.001), be admitted to an ICU within 30 days of death (12.5% vs 19.7%, P<.001), or have >1 emergency room visit within 30 days of death (13.1 vs 14.7, P=.09). CONCLUSIONS: Older men with metastatic lung or colorectal cancer treated in the VHA healthcare system received less aggressive end-of-life care than similar men in fee-for-service Medicare. This may result from the absence of financial incentives for more intensive care in the VHA or because this integrated delivery system is better structured to limit potentially overly aggressive care. Additional studies are needed to assess whether men undergoing less aggressive end-of-life care also experience better outcomes. Copyright (c) 2010 American Cancer Society.
BACKGROUND: Treatment of older cancerpatients at the end of life has become increasingly aggressive, despite the absence of evidence for better outcomes. We compared aggressiveness of end-of-life care of older metastatic cancerpatients treated in the Veterans Health Administration (VHA) and those under fee-for-service Medicare arrangements. METHODS: Using propensity score methods, we matched 2913 male veterans who were diagnosed with stage IV lung or colorectal cancer in 2001-2002 and died before 2006 with 2913 similar men enrolled in fee-for-service Medicare living in Surveillance, Epidemiology, and End Result (SEER) areas. We assessed chemotherapy within 14 days of death, intensive care unit (ICU) admissions within 30 days of death, and >1 emergency room visit within 30 days of death. RESULTS: Among matched cohorts, men treated in the VHA were less likely than men in the private sector to receive chemotherapy within 14 days of death (4.6% vs 7.5%, P<.001), be admitted to an ICU within 30 days of death (12.5% vs 19.7%, P<.001), or have >1 emergency room visit within 30 days of death (13.1 vs 14.7, P=.09). CONCLUSIONS: Older men with metastatic lung or colorectal cancer treated in the VHA healthcare system received less aggressive end-of-life care than similar men in fee-for-service Medicare. This may result from the absence of financial incentives for more intensive care in the VHA or because this integrated delivery system is better structured to limit potentially overly aggressive care. Additional studies are needed to assess whether men undergoing less aggressive end-of-life care also experience better outcomes. Copyright (c) 2010 American Cancer Society.
Authors: Melissa W Wachterman; Stuart R Lipsitz; Steven R Simon; Karl A Lorenz; Nancy L Keating Journal: J Pain Symptom Manage Date: 2013-11-22 Impact factor: 3.612
Authors: Sangeeta C Ahluwalia; Diana M Tisnado; Anne M Walling; Sydney M Dy; Steven M Asch; Susan L Ettner; Benjamin Kim; Philip Pantoja; Hannah C Schreibeis-Baum; Karl A Lorenz Journal: J Palliat Med Date: 2015-07-17 Impact factor: 2.947
Authors: Anne M Walling; Diana Tisnado; Susan L Ettner; Steven M Asch; Sydney M Dy; Philip Pantoja; Martin Lee; Sangeeta C Ahluwalia; Hannah Schreibeis-Baum; Jennifer L Malin; Karl A Lorenz Journal: J Pain Symptom Manage Date: 2016-07-09 Impact factor: 3.612
Authors: William F Pirl; Joseph A Greer; Kelly Irwin; Inga T Lennes; Vicki A Jackson; Elyse R Park; Daisuke Fujisawa; Alexi A Wright; Jennifer S Temel Journal: J Oncol Pract Date: 2015-03-31 Impact factor: 3.840
Authors: Claire O'Hanlon; Christina Huang; Elizabeth Sloss; Rebecca Anhang Price; Peter Hussey; Carrie Farmer; Courtney Gidengil Journal: J Gen Intern Med Date: 2016-07-15 Impact factor: 5.128
Authors: Nancy L Keating; Mary Beth Landrum; Elizabeth B Lamont; Samuel R Bozeman; Lawrence N Shulman; Barbara J McNeil Journal: J Natl Cancer Inst Date: 2012-12-28 Impact factor: 13.506